Optimization and in vivo evaluation of innovative theranostic imaging probes using Anticalin and PASylation technologies (A08)

使用 Anticalin 和 PASylation 技术对创新治疗诊断成像探针进行优化和体内评估 (A08)

• 批准号: 236908187
• 金额: --
• 依托单位: Klinik und Poliklinik für Nuklearmedizin
• 依托单位国家: 德国
• 项目类别: Collaborative Research Centres
• 财政年份: 2013
• 资助国家: 德国
• 起止时间: 2012-12-31 至 2020-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/236908187?language=en
• 关键词: Optimization; vivo; evaluation; innovative; theranostic

Within the new funding period, Project A8 will focus on the development and preclinical evaluation of novel imaging probes such as Anticalins, Fab fragments and other binding proteins as well as bifunctional fusion proteins for pretargeting radio-immuno therapy and diagnostics. Using state of the art protein design concepts, we will apply innovative methods for protein radiolabeling and plasma half-life optimization. Oncologically relevant targets such as the established cell surface receptors/proteins HER2, CEA, PSMA, ED-B, PD-L1 as well as tumor-specific sugars will be addressed in this project.

在新的资助期内，项目A8将侧重于新型成像探针的开发和临床前评估，如抗菌素、Fab片段和其他结合蛋白以及用于预靶向放射免疫治疗和诊断的双功能融合蛋白。使用最先进的蛋白质设计概念，我们将应用创新的方法进行蛋白质放射性标记和血浆半衰期优化。与肿瘤相关的靶点，如已建立的细胞表面受体/蛋白HER2、CEA、PSMA、ED-B、PD-L1以及肿瘤特异性糖将在该项目中解决。